AFP
IMGN

Ausdal Financial Partners’s Immunogen Inc IMGN Stock Holding History

Ausdal Financial Partners’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-77
Closed -$1K – 1070
2015
Q4 		$1K Buy
+77
New +$948 ﹤0.01% 1280

Other funds holding IMGN

ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Ausdal Financial Partners's IMGN Position: Q1 2016 in Review

Ausdal Financial Partners sold out of Immunogen Inc (IMGN) in Q1 2016, closing a stake of 77 shares — an estimated $1K sold.

Ausdal Financial Partners first reported a position in IMGN in Q4 2015 and held it in 1 quarter. The position peaked at $1K in Q4 2015. 143 funds tracked by Wall St. Rank hold IMGN as of Q1 2016.

  • Ausdal Financial Partners reported no remaining Immunogen Inc position as of Q1 2016 after selling out during the quarter.
  • Ausdal Financial Partners sold 77 Immunogen Inc shares in Q1 2016, an estimated $1K.
  • Ausdal Financial Partners first reported a position in Immunogen Inc in Q4 2015 and held it in 1 quarter.
  • Ausdal Financial Partners's Immunogen Inc position peaked at $1K in Q4 2015.
  • 143 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2016.

Based on Ausdal Financial Partners's 13F filing for Q1 2016, filed 5 May 2016.